Polygenic risk scoring for common complex disease

Dr. Estelle Giraud
Navnetics
(Formerly Illumina)

Join Dr. Estelle Giraud as she provides an overview on Polygenic Risk Scores (PRS), why they are clinically relevant and how they may be used in the future. Dr. Giraud will also discuss the Illumina technologies that enable PRS research today.

Dr Estelle Giraud is CEO and founder of Navnetics, an early stage startup that is focused on building a platform for people to have custody and control over their health information, particularly their personal genomic information; to ultimately build a complete mobile digital representation of ones’ own biology over time. Prior to Navnetics, Estelle spent ~8 years at Illumina across the Americas and Australia, most recently she led a team of Array and Consumer Genomics Sales Specialists for the Americas region. Prior to Illumina, Estelle worked as an Assistant Professor (Research) at the University of Western Australia, and held a joint appointment teaching undergraduate students in Integrated Genomics and Bioinformatics at Zhejiang University, China. She obtained her PhD from the University of Western Australia in 2009. She is passionate about science and the promise of technology advances in genomics in realizing the vision of precision medicine.